sebelipase alfa (kanuma) Report issue

Biologics Recombinant protein Orphan Drug FDA Approved FDA First in Class Fast Track FDA Priority Review FDA

Active Ingredient History

  • Now
Sebelipase alfa, sold under the brand name Kanuma, is a recombinant form of the enzyme lysosomal acid lipase (LAL) that is used as a medication for the treatment of lysosomal acid lipase deficiency (LAL-D). It is administered via intraveneous infusion. It was approved for medical use in the European Union and in the United States in 2015.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$779.5950 - $1005.6080
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

kanuma | lipa | sbc-102 | sebelipase alfa


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue